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Samples from patients at high risk for invasive aspergillosis (IA) were prospectively collected and analyzed for the presence of
molecular markers of fungal infection. Serum specimens were screened for galactomannan and AspergillusDNA, and whole-
blood specimens were screened only for AspergillusDNA. Fungal infections were categorized according to the European Organi-
zation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and
Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria. Forty-seven cases (proven and probable IA) and 31 controls
(no evidence of IA) were selected retrospectively for this case-control study, comprising 803 samples, in order to determine the
performance of whole-blood PCR, serum PCR, and serum galactomannan testing. Although no single assay was able to detect
every case of IA, a combination of different assays provided the best performance. There was no significant difference between
the use of whole-blood and serum specimens for PCR-based diagnosis of IA, but there was a trend for whole blood to be more
sensitive (85% versus 79%) and to yield an earlier positive result (36 days versus 15 days) than for serum. However, DNA extrac-
tion from serum specimens is easier and faster than that fromwhole-blood specimens, and it allows the same specimen to be
used for both galactomannan and PCR assays. In conclusion, the appropriate sample type for DNA extraction should be deter-
mined by the local requirements and the technical platforms available at each individual center. A combination of biomarker
tests offered the best diagnostic utility for detecting IA.
Invasive aspergillosis (IA) is a major complication in immuno-compromised patients, particularly individuals with acute leu-
kemia or those receiving allogeneic stem cell transplantation (1).
Mortality rates remain high, at up to 89% (2, 3); this is linked to
difficulties in diagnosing IA due to nonspecific and late clinical
signs and to the insensitivities of conventional laboratory diagno-
sis methods (4, 5). Consequently, empirical therapy is frequently
used, at a great cost, and it exposes patients to unnecessary drug
side effects and toxicity. Early diagnosis is paramount, and sensi-
tive molecular assays have the potential to improve diagnosis and
patient outcome by providing alternative preemptive strategies.
PCR testing can be used as a screening tool to exclude IA (6).
Therefore, high-frequency sampling is required, which favors the
use of easily obtainable specimen types, such as blood. The fungal
load is very limited in blood, and a high analytical sensitivity is
essential for reducing the number of false-negative results (7, 8).
Different blood fractions have been evaluated for molecular
tests, but direct comparisons of PCR performance are limited.
DNA extraction from whole blood (WB) is technically demand-
ing, requiring greater standardization than DNA extraction from
serum (or plasma). Guidelines for DNA extraction fromWB and
serum specimens and for DNA detection were published by the
European Aspergillus PCR Initiative (EAPCRI) (9, 10). Extraction
efficacy was influenced by sample type, the amount of clinical
material, and the protocol used (11).
The exact origin of Aspergillus DNA in blood is unclear since
the fungus is rarely recovered from the bloodstream in cases of IA.
Recent studies in murine models of IA and in vitro have indicated
that cell-free fungal DNA is released by actively growing mycelia
(12). Additionally, cell-free fungal DNA in blood might be a by-
product of phagocytosis or the result of antifungal therapy. Cell-
bound fungal DNA is thought to be linked to free or phagocytosed
hyphal elements in the circulation (13).
Despite the existence of standardized methodologies for test-
ing both serum and WB specimens, there have been only limited
comparisons of their performance. In this case-control study, we
describe a multicenter approach (University Hospitals of Cardiff
and Wuerzburg and St. James’s Hospital Dublin) comparing
DNA detection of Aspergillus in serum and WB specimens ob-
tained from patients at high risk for IA. Both specimen types were
collected in parallel; WB was analyzed prospectively by PCR,
whereas serum was prospectively tested by galactomannan (GM)
enzyme-linked immunosorbent assay (ELISA) and stored at
20°C prior to retrospective serum PCR testing. Patients were
selected as either cases (diagnosed with proven or probable IA
categorized according to the current European Organization for
Research and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group, National Institute of Allergy and Infectious
Diseases Mycoses Study Group [EORTC/MSG] criteria [14]) or
controls (categorized as no evidence of fungal disease). All DNA
Received 20 December 2012 Returned for modification 21 January 2013
Accepted 15 February 2013
Published ahead of print 20 February 2013
Address correspondence to Juergen Loeffler, loeffler_j@klinik.uni-wuerzburg.de.
* Present address: C. O. Morton, University of Western Sydney, Sydney, Australia;
Melinda Paholcsek, Department of Human Genetics, Medical and Health Science
Centre, University of Debrecen, Debrecen, Hungary.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.03322-12
May 2013 Volume 51 Number 5 Journal of Clinical Microbiology p. 1445–1450 jcm.asm.org 1445
extraction methods were compliant with published EAPCRI rec-
ommendations (9, 10).
MATERIALS AND METHODS
Study design. Allogeneic stem cell transplant recipients (alloSCT) and
patients receiving myelosuppressive chemotherapy with an expected du-
ration of 10 days of neutropenia (leukocyte count, 1,000/l) were
included in the study. Between 2006 and 2011, blood and serum samples
were taken twice weekly from patients at high risk for invasive fungal
disease. Signs and symptoms of IA were collected together with other
microbiological data from patient charts in order to categorize the onset
and type of fungal infection according to the revised EORTC/MSGcriteria
(14). WB specimens were analyzed prospectively. In parallel, serum sam-
ples were used for galactomannan quantification. PCR results were not
subject to EORTC/MSG classification.
In accordance with EORTC/MSG classification criteria, cases (proven
or probable IA) and controls (unclassified patients with no signs of IA)
were retrospectively selected. Frozen samples from these patients were
thawed and used to extract DNA from serum.
The study was approved by the local ethics committees of the Univer-
sity Hospitals of Wuerzburg and St. James’s Hospital Dublin. In Cardiff,
samples were prospectively tested as part of routine diagnostic care. PCR
testing of serum samples was performed as a retrospective anonymous
evaluation of the diagnostic service and needed no ethical approval. Re-
sults from all assays were anonymized by the referring center prior to
retrospective testing.
DNA extraction fromWB. All DNA extraction steps were performed
in a class II laminar-flow cabinet and were compliant with EAPCRI rec-
ommendations (9).
WB was extracted as described previously (15, 16). Briefly, red and
white cells from 3 ml of EDTA blood were lysed and centrifuged. The
pellet was bead beaten to lyse fungal cells. DNAwas isolated by a commer-
cially available kit (High Pure PCR template preparation kit; Roche). The
elution volumewas 100l inWuerzburg and 65l in Dublin andCardiff.
In each extraction procedure, at least one negative control was included.
In Cardiff and Dublin, positive extraction controls were also included.
DNA extraction from serum. All steps for extracting serum from
DNAwere performed in a class II laminar-flow cabinet and were compli-
ant with EAPCRI recommendations (10).
In Wuerzburg and Dublin, DNA from 1 ml of serum was extracted
using theQIAampUltraSens virus kit (Qiagen,Hilden,Germany) accord-
ing to the manufacturer’s instructions. The elution volume was adjusted
to 35 l. In each extraction procedure, at least one negative control was
included. Extraction performance was monitored by testing both blinded
and known simulated positive-control specimens.
In Cardiff, 0.5 ml of serum was used. DNA was purified by using the
High Pure PCR template preparation kit (Roche) (17). Briefly, 0.5 ml of
serum was mixed with 0.4 ml of binding buffer and 80 l of recombinant
proteinase K (Roche), and the mixture was incubated at 70°C for 10 min.
Two hundred microliters of isopropanol was added and mixed by pipette
before the entire specimen was applied to the spin column by centrifuga-
tion at 8,000 g for 1 min. Other than these modifications, the kit was
used in accordance with the manufacturer’s instructions, using an
elution volume of 65 l. Positive and negative serum extraction con-
trols were included in every run.
DNA amplification and detection. All PCR methods were validated
by testing different EAPCRI panels and showed comparable performance
in detecting the thresholds set by the EAPCRI (9, 10).
In Wuerzburg, an Aspergillus-specific real-time PCR assay targeting
the internal transcribed spacer 1 (ITS1)-5.8S rRNA gene region (16, 18)
was used to detect fungalDNA. Briefly, 21-l reactionmixtures contained
0.3 M primer Asp fum_F degen, 0.6 M primer Fungi 5.8_R, 0.15 M
hydrolysis probe ITS-PF, 10l TaqMan gene expressionmaster mix (Ap-
plied Biosystems), and 10 l template DNA. Asp fum_F degen was used
instead of Asp fum_F to increase sensitivity for non-fumigatus species of
Aspergillus.
Amplification was carried out in a StepOnePlus machine (Applied
Biosystems)with the following steps: 50°C for 2min, 95°C for 10min, and
55 cycles of 95°C for 15 s, 54°C for 30 s, and 72°C for 30 s. Negative
and positive PCR controls were included in each run. Samples were ana-
lyzed in triplicate (WB) or duplicate (serum). PCR efficiency was 92.5%
for A. fumigatus, 90.3% for A. terreus, and 90.1% for A. flavus. No cross-
reactivity with other fungi or human genomic DNA was observed (18).
This assay detected all clinically relevant Aspergillus species (16).
The assay inDublinwas amodified version of the previously described
protocol of Wuerzburg (16). Briefly, 20-l reaction mixtures contained
0.25 M primer Asp fum_F, 0.25 M primer Fungi5.8_R, 0.375 M
hydrolysis probe ITS-PF, 10l TaqMan gene expressionmaster mix (Ap-
plied Biosystems), and 7l template DNA. Amplification was carried out
on a 7500 real-time PCR machine (Applied Biosystems) with the follow-
ing steps: 95°C for 10min and 45 cycles of 95°C for 15 s and 60°C for 30 s).
Sensitivity was 94% for A. fumigatus, which was the only Aspergillus spe-
cies detected. No cross-reactivity was observed for other fungi and human
DNA (12, 16, 19).
In Cardiff, the Aspergillus real-time PCR test was performed as a sin-
gle-round assay using a Corbett Rotor-Gene 3000 instrument targeting
the 28S rRNA gene, modified to allow greater template DNA input (15
l), in a final reaction mixture volume of 50 l (6). Extraction controls,
PCR controls in the form of cloned PCR products (300, 30, and 3 input
copies), and no-template molecular-grade water were included to moni-
tor PCRperformance. PCRpositivity was determined using a threshold of
45 cycles. PCR efficiency was 90% when testing DNA extracts from
both serum and WB samples. The assay was specific to Aspergillus and
Penicillium species and did not cross-react with other fungal, yeast, or
human DNA.
At all centers, duplicate and triplicate (for serum and WB samples,
respectively) PCR testing allowed different interpretations of test positiv-
ity. In this study, one positive PCR replicate was considered significant.
Galactomannan ELISA. In all three centers, GM was quantified in
serum and bronchoalveolar lavage (BAL) samples using the Platelia
Aspergillus GM ELISA (Bio-Rad) according to manufacturer’s instruc-
tions, with a cutoff optical density of 0.5. Bronchoscopy was performed
whenever necessary and if the general condition of the patient allowed.
GM testing of BAL samples from Dublin patients was not performed.
Data analysis. Patients with proven or probable IA according to the
EORTC/MSG criteria (14) were classified as true positives, and those di-
agnosed as unclassified were classed as true negatives. Diagnostic perfor-
mance parameters were calculated using previously described methods
(20). Two-sided P values were calculated using Fisher’s exact test. Paired
and unpaired 95% confidence intervals were calculated using the method
of Newcombe (21, 22).
RESULTS
Patient details.According to the EORTC/MSG criteria (14), there
were 47 cases (7 proven and 40 probable IA) and 31 controls (no
evidence of IA) selected on the basis of the availability of serum
samples for additional molecular testing. Controls were selected
randomly but in temporal correlation to patients with proven and
probable IA.
These 78 patients provided 808 samples (500 from cases, 308
from controls), with a mean of 10.4 specimens per patient (range,
3 to 32). Patient demographics are shown in Table 1.
Performance of molecular assays. (i) Sample positivity. Of
the 808 clinical samples collected, 803 samples were available for
GM ELISA testing, 790 samples forWB PCR, and 754 samples for
serum PCR testing (Table 2). In total, GM yielded 146 positive
results (18.2%), WB yielded 145 positive results (18.4%), and se-
rum yielded 123 positive results (16.3%).
Springer et al.
1446 jcm.asm.org Journal of Clinical Microbiology
Analysis of IA cases for their positivity showed that all three
biomarker assays generated a high number of positives and there
were no significant differences in sample positivity between assays
(Table 2). In contrast, in the control group, very few samples
tested positive for GM (Table 2). Interestingly, only one sample
showed concordant positivity for WB and serum testing. The po-
tential false-positive rate in WB PCR was greater than the rates
generated by both GM and serum PCR; for all assays, the sample
positivity rate in cases was significantly greater than that generated
by the controls. Themean number of samples detected in patients
with proven or probable IA by each assay was 3.1 (range, 0 to 12)
by GM, 2.7 (range, 0 to 8) byWB PCR, and 2.5 (range, 0 to 10) by
serum PCR. The percentage of these patients with more than one
positive assay result was 57.4% (9), 63.8% (13), and 59.6% (6) for
GM, WB, and serum, respectively. From 27 patients with a GM
positive result, two could not be confirmed byWB PCR and three
by serum PCR. From 30 patients with a WB PCR positive result,
five could not be confirmed by GM or by serum PCR. From 28
patients with a serum PCR positive result, seven could not be
confirmed by GM and two by WB PCR.
The individual sample concordance (observed agreement
[kappa]) forGMversusWBPCR,GMversus serumPCR, andWB
versus serum PCR was 76.7% (95% confidence interval [CI], 72.9
to 80.5) and kappa, 0.22 (95% CI, 0.13 to 0.31); 81.3% (95% CI,
77.4 to 84.6) and kappa, 0.35 (95% CI, 0.26 to 0.44); and 77.9%
(95% CI, 73.8 to 81.6) and kappa, 0.23 (95% CI, 0.14 to 0.32),
respectively.
(ii) Patient positivity. Using a single positive assay, patient
positivity in the case group (n 47) was 80.9% for GM, 85.1% for
WB, and 78.7% for serum PCR. In the control group (n  31),
3.2% of the patients were positive by GM, 16.1% by serum, and
35.5% by WB (Table 3). There were nine cases not detected by
GM, seven by WB, and 10 by serum. Twenty-eight cases were
detected by all three biomarker assays, 12 by two assays (five by
GM andWB assays, five byWB and serum assays, two by GM and
serum assays), and seven by only one assay (two serum, two WB
PCR, three GM). The four cases detected by only one PCR assay
were classified using a positive GM from a BAL sample or Asper-
gillus culture from sputum with the EORTC/MSG microbiologi-
cal criteria. No cases were negative by all tests. As mentioned be-
fore, if only one test was performed, positivity in some patients
was not detected.
Fifteen BAL samples were tested by GM ELISA. All 12 positive
tests were due to BAL samples from IA cases. Aspergillus cultures
from clinical samples of IA cases (BAL, sputum, sinus aspirates, or
brain tissue specimens) were positive in 11 samples (A. fumigatus,
n 10; A. niger, n 1).
To investigate further the differences in biomarker positivity
values, we analyzed clinical data, including blood counts, donor
type, and the use of alemtuzumab and antimold effective drugs
(assay positivity under treatment) in these patients. No correla-
tion between these clinical data and the differences in diagnostic
performance could be demonstrated (data not shown).
In a further analysis, the first positive test had to be confirmed
by a second positive assay within 11 days. This could have been by
the same assay or by any other test, resulting in 6 different com-
binations of GM/GM, WB/WB, serum/serum, GM/WB, GM/se-
rum, andWB/serum. The time interval of 11 days was determined
TABLE 1 Patient demographics
Patient characteristica Value(s)
No. of patients 78
Male/female ratio 53:25
Median age (yr) of males (range) 53 (18–75)
Median age (yr) of females (range) 51 (20–72)
Mean no. of specimens per patient (range) 10.4 (3–32)
No. of AML patients 36
No. of ALL patients 10
No. of patients with other underlying diseasesb 32
a AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia.
b Includes chronic lymphoblastic leukemia (CLL) (n 7), chronic myeloid leukemia
(CML) (n 5), chronic eosinophilic leukemia (CEL) (n 1), Hodgkin’s lymphoma
(n 5), non-Hodgkin’s lymphoma (n 5), multiple myeloma (n 2),
myelodysplastic syndrome (n 3), immunocytoma (n 1), and myelofibrosis (n 3).
TABLE 2 Biomarker sample positivity rates
Assay
No. of positive results/total (%)
% difference in positivity: case
vs. control (P value)
% difference in positivity between assays (P value)
Cases Controls Assays Cases Controls
GM ELISA 145/495 (29.3) 1/308 (0.3) 29 (0.0001)a GM vs WBb 4.3 (0.1515) 5.3 (0.0001)a
WB PCR 128/490 (26.1) 17/300 (5.7) 20.4 (0.0001)a WB vs serumc 0.7 (0.8794) 4.3 (0.0149)a
Serum PCR 118/467 (25.3) 5/287 (1.7) 23.6 (0.0001)a Serum vs GMd 4.1 (0.1859) 1.4 (0.2123)
a Statistically significant difference.
b A total of 486 samples from cases and 300 samples from controls were tested by WB PCR and GM ELISA.
c A total of 458 samples from cases and 281 samples from controls were tested by WB PCR and serum PCR.
d A total of 466 samples from cases and 287 samples from controls were tested by serum PCR and GM ELISA.
TABLE 3 Patient positivity using individual and combinations of
biomarker assays
Assay
Positivity resultsa
P valueb
Cases (n 47) Controls (n 31)
No.
positive
% positive
(95% CI)
No.
positive
% positive
(95% CI)
GM 38 80.9 (67.5–89.6) 1 3.2 (0.6–16.2) 0.0001
WB PCR 40 85.1 (72.3–92.6) 11 35.5 (21.1–53.1) 0.0001
Serum PCR 37 78.7 (65.1–88.0) 5 16.1 (7.1–32.6) 0.0001
Combination
testingc
GM/GM 23 48.9 (35.3–62.8) 0/31 0 (0–11.3) 0.0001
GM/WB 32 68.1 (53.8–79.6) 0 0 (0–11.3) 0.0001
GM/serum 28 59.6 (45.3–72.4) 0 0 (0–11.3) 0.0001
WB/WB 22 46.8 (33.3–60.8) 2 6.5 (1.8–20.7) 0.0002
WB/serum 28 59.6 (45.3–72.4) 1 3.2 (0.6–16.2) 0.0001
Serum/serum 24 51.1 (37.2–64.7) 0 0 (0–11.3) 0.0001
a Positivity in cases was significantly greater than that in controls for all assays and
combinations assessed.
b P value calculated for difference in positivity between cases and controls.
c As an example, the combination GM/GMmeans that a first positive test had to be
confirmed by a second positive test within 11 days.
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as optimal by receiver operating characteristic (ROC) curve anal-
ysis (data not shown).
This second analysis markedly reduced the number of false-
positive patients in the control group for all combinations; only
the combinations WB/WB and WB/serum detected control pa-
tients (2 and 1 patients, respectively; see Table 3). In the case group
(n  47), the various combinations performed differently, with
the combination GM/WB yielding the highest positivity (68.1%;
Table 3). Use of the same biomarkers to confirm positivity re-
sulted in lower positivity rates.
Diagnostic parameters were calculated for single or confirmed
positive assays. For single positive assays,WB had the highest sen-
sitivity, whereas specificity and positive predictive value (PPV)
were highest for GM, and specificity was significantly greater than
in WB PCR (difference, 32.3% [95% CI, 11.6 to 50.4%; P 
0.0026]) (Table 4). However, as GM was used to define probable
disease according to the EORTC/MSG criteria, its performance
reflects inclusion bias and should not be used for comparative
purposes. The negative predictive value (NPV) was similar for all
three assays, ranging from 72.2% to 76.9%, but it must be noted
that PPV andNPV are significantly affected by disease prevalence,
which is artificially high in case-control studies (Table 4).
When a second assay was used to confirm positivity, the high-
est sensitivity was achieved by the combination of GM/WB fol-
lowed by GM/serum. Specificity and PPV were excellent for all
combinations (91%) (Table 4).
Timing of assay positivity relative to CT scan or biopsy. To
analyze the temporal relationship between the differentmolecular
assays, the first positive results in each assay of a proven or prob-
able case were compared to the definitive diagnosis based on com-
puted tomography (CT) scan, biopsy, or tissue culture (time point
“zero”). Patients who had aCT scan prior to the beginning of PCR
and ELISA screening (n  10) were excluded from this specific
analysis. GM positivity preempted CT in 25 cases, WB in 27, and
serum in 24 cases.
Prior to the definitive diagnosis based on CT scan, biopsy, or
tissue culture, WB preceded the CT scan by a mean of 36 days
(range, 1 to 118),GMby 24 days (range, 1 to 118), and serumby 15
days (range, 1 to 79). In 33 patients (70%) with proven or proba-
ble IA, the diagnosis might have been established earlier if it had
been based on a positive PCR test instead of the CT scan, biopsy,
or tissue culture. Twenty-eight cases had a confirmation of the
first positive assay by a second assay (PCR or GM) prior to the CT
scan. In 2 cases, the confirmation was concordant with the CT
scan, and in 1 case only, a positive CT scan confirmed the GM
result.
The diagnostic means (molecular assays and CT scan or
biopsy) were compared to show the earliest signs that suggested
IA in each patient. In 22 patients, WB PCR became positive
prior to the other tests (mean, 37 days; range, 1 to 118 days), in
17 patients, GM was the first assay to be positive (mean, 32
days; range, 1 to 118 days), and in 14 patients, serum PCR
showed the earliest signs of IA (mean, 14 days; range, 1 to 45
days) prior to diagnosis based on CT scan or biopsy).
DISCUSSION
Sensitive molecular assays leading to an earlier diagnosis of IA are
needed for good patient prognosis. Several clinical studies have
already shown the potential of PCR in this area (23), but the op-
timal clinical material to be used for diagnosis has yet to be deter-
mined. Our aim was to compare WB and serum directly in a
cohort of patients at high risk for IA. All extraction methods used
in this study were compliant with published EAPCRI guidelines
(9, 10).
Besides its efficient DNA extraction and highly sensitive detec-
tion, performing PCR in duplicate contributed to increased sen-
sitivity (24). Since the fungal load in blood is low (7, 8), the detec-
tion of pathogen DNA might be very close to the limit of PCR
detection (LoD). Reproducibility within this quantification cycle
(Cq) range is not consistent (25) and can lead to false-negative
results. Duplicate testing increases the chance of detecting low
concentrations of DNA but might give nonreproducible results
concerning not only PCR technology itself, but also the different
material used for DNA extraction. To overcome this problem, the
enrichment of fungal target DNA by a higher extraction efficacy,
amount of starting material, and frequency of screening might be
beneficial. In this study, single positive results were considered
positive, as recommended previously (18, 25).
We analyzed our data in two different ways, first by individual
assay positivity and then by using a second assay within 11 days as
TABLE 4 The individual and combined diagnostic performance of GM ELISA, WB, and serum PCR
Assay
Performance value (% [95% CI])a
LRb LR DORcSensitivity Specificity PPV NPV
GM 80.9 (67.5–89.6) 96.8 (83.8–99.4) 97.4 (86.8–99.6) 76.9 (61.7–87.4) 25.3 0.20 126.5
WB PCR 85.1 (72.3–92.6) 64.5 (47.0–78.9) 78.4 (65.4–87.5) 74.1 (65.4–87.5) 2.4 0.23 10.4
Serum PCR 78.7 (65.1–88.0) 83.9 (67.4–92.9) 88.1 (75.0–94.8) 72.2 (56.0–84.2) 4.9 0.25 19.6
Combination testingd
GM/GM 48.9 (35.3–62.8) 100 (89.0–100) 100 (85.7–100) 56.4 (43.3–68.7) 489 0.51 958.9
GM/WB 68.1 (53.8–79.6) 100 (89.0–100) 100 (89.3–100) 67.4 (53.0–79.1) 681 0.32 2,128.1
GM/serum 59.6 (45.3–72.4) 100 (89.0–100) 100 (87.9–100) 62.0 (48.2–74.1) 596 0.40 1,490
WB/WB 46.8 (33.3–60.8) 93.5 (79.3–98.2) 91.7 (74.2–97.7) 53.7 (40.6–66.3) 7.2 0.57 12.6
WB/serum 57.4 (43.3–70.5) 96.8 (83.8–99.4) 96.4 (82.3–99.4) 60.0 (46.2–72.4) 17.9 0.44 40.7
Serum/serum 53.2 (39.2–66.7) 100 (89.0–100) 100 (86.7–100) 58.5 (45.1–70.7) 532 0.47 1,131.9
a PPV, positive predictive value; NPV, negative predictive value.
b LR, likelihood ratio.
c DOR, diagnostic odds ratio.
d As an example, the combination GM/GMmeans that a first positive test had to be confirmed by a second positive test within 11 days.
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confirmation. In the first analysis, WB reached the best sensitivity
but the lowest specificity. The combination WB/WB performed
the worst, but in combination with another assay (GM), WB
showed the best sensitivity, specificity, and diagnostic odds ratio
(DOR) values. The second highest DORwas achieved by the com-
bination ofGMwith serum.All combinations using different con-
firmatory assays (GM/WB, GM/serum, and WB/serum) were su-
perior to confirmation using the same assay as the first (GM/GM,
WB/WB, and serum/serum). No cases weremissed when using all
three assays, and if all were negative, IA could be confidently ex-
cluded. In this study, NPVs were lower than in previous studies,
reflecting the artificial disease prevalence in case-control studies;
the incidence for this study was 60.2%. If the sensitivity and spec-
ificity values determined in this study are applied to the same size
population, but with a more representative incidence of 10%, the
NPV for all assays is97%, supporting a screening role to exclude
diseases in routine clinical practice.
As reported previously (7), the use of one assay was insufficient
for the diagnosis of IA, but a second complementary assay mark-
edly improved specificity and PPV. Based on the results of a large
prospective study in which we evaluated the utility of combining
real-time PCR with galactomannan surveillance in high-risk pa-
tients (15), together with the findings of the present study, we
recommend the use of a second confirmatory assay that is differ-
ent from GM for the detection of IA. This could be PCR from
either serum or WB. Furthermore, a second confirmatory test
reduced false positivity within individual assays. More than 35%
of the control patients were positive by a single positiveWB assay;
by using an additional WB confirmatory assay (within 11 days),
false positivity was reduced by 29.0% (95% CI, 8.8 to 47.2%; P
0.0106).
This reduction might be interpreted in different ways. First,
control patients that were PCRpositive were accurately defined by
EORTC/MSG criteria, and false-positive results were generated by
an oversensitive molecular assay resulting in low specificity. Sec-
ond, PCR-based methods potentially have higher sensitivity to
detect more cases, including subclinical manifestations of IA or
potential exposure to the organism, an important factor consid-
ering that all patients were at high risk of developing IA. The
accuracy of biomarker diagnosis is increased in patients who are
found to be positive by more than one biomarker. The revised
EORTC/MSG criteria were defined to determine accurate diagno-
sis of disease, principally for clinical trials, whereas biomarker
detection tries to preempt disease by targeting the early infective
process. This allows early initiation of empirical therapy, resulting
in a better prognosis for the patient. However, 19 patients classi-
fied as having proven or probable IA were not detected by one, or
even two, molecular methods. No PCR inhibition was detected,
but the release of fungal DNA and antigens is poorly understood
and is influenced by antifungal treatment (26–28). Almost all
proven or probable cases received antimold effective drugs at
some point, and diagnostic performance might be negatively in-
fluenced by this treatment.
Other clinical studies have attempted to determine what blood
fraction is optimal for PCR-based detection of IA. Loeffler et al.
(29) compared WB and plasma and found WB to be more sensi-
tive. Plasmawas also determined to be less sensitive than serum or
WB using different blood fractions spiked with free Aspergillus
DNA (30).
More recently, Bernal-Martinez et al. (31) compared serum
and WB samples obtained from 26 patients. In their study, they
did not observe any significant differences in performance be-
tween the samples and they concluded by recommending serum
for Aspergillus detection, due to its convenience.
Early detection of IA is necessary for achieving a good patient
prognosis. Therefore, in addition to assay sensitivity, the timing of
assay positivity is important. With regard to the earliest positive
assay, WB detected the most cases at the earliest time points, pre-
ceding GM and serum by 12 and 21 days, respectively, in compar-
ison to CT scanning and biopsy or by 5 and 22 days, respectively.
In the study of Meije et al. (32), Aspergillus fumigatus DNAemia
precededCTandGMby an average of 21 and 68days, respectively.
The same trend was reported by Challier et al. (7). In this study,
WB preceded the CT scan by a mean of 36 days, GM by 26 days,
and serum by 15 days.
In summary, there was no significant difference between the
use of WB and serum samples for PCR-based diagnosis of IA.
However, there was a trend for WB to be more sensitive (85%
versus 79%) and show earlier positive results (36 days versus 15
days) compared to serum. Against this finding, false positivity is
reduced using serum specimens, and they are also easier and faster
to process thanWB and can be used for simultaneous GM testing.
A combination of biomarker testing offered the best diagnostic
utility. Individual users should determine the sample type that
meets the particular requirements of their individual center.
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